Literature DB >> 18459947

Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study.

D M Wunder1, C A Fux, N A Bersinger, N J Mueller, B Hirschel, M Cavassini, L Elzi, P Schmid, E Bernasconi, B Mueller, H Furrer.   

Abstract

OBJECTIVES: We compared androgen and gonadotropin values in HIV-infected men who did and did not develop lipoatrophy on combination antiretroviral therapy (cART).
METHODS: From a population of 136 treatment-naïve male Caucasians under successful zidovudine/lamivudine-based cART, the 10 patients developing lipoatrophy (cases) were compared with 87 randomly chosen controls. Plasma levels of free testosterone (fT), dehydroepiandrosterone (DHEA), follicle-stimulating hormone and luteinizing hormone (LH) were measured at baseline and after 2 years of cART.
RESULTS: At baseline, 60% of the cases and 71% of the controls showed abnormally low fT values. LH levels were normal or low in 67 and 94% of the patients, respectively, indicating a disturbance of the hypothalamic-pituitary-gonadal axis. fT levels did not significantly change after 2 years of cART. Cases showed a significant increase in LH levels, while controls showed a significant increase in DHEA levels. In a multivariate logistic regression model, lipoatrophy was associated with higher baseline DHEA levels (P=0.04), an increase in LH levels during cART (P=0.001), a lower body mass index and greater age.
CONCLUSIONS: Hypogonadism is present in the majority of HIV-infected patients. The development of cART-related lipoatrophy is associated with an increase in LH and a lack of increase in DHEA levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18459947     DOI: 10.1111/j.1468-1293.2008.00578.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  6 in total

Review 1.  Management of prostate cancer in HIV-positive patients.

Authors:  Matthew S Wosnitzer; Franklin C Lowe
Journal:  Nat Rev Urol       Date:  2010-04-27       Impact factor: 14.432

Review 2.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

Review 3.  HIV and the Pituitary Gland: Clinical and Biochemical Presentations.

Authors:  Joyce Youssef; Rohan Sadera; Dushyant Mital; Mohamed H Ahmed
Journal:  J Lab Physicians       Date:  2021-05-19

4.  Premature decline of serum total testosterone in HIV-infected men in the HAART-era.

Authors:  Vincenzo Rochira; Lucia Zirilli; Gabriella Orlando; Daniele Santi; Giulia Brigante; Chiara Diazzi; Federica Carli; Cesare Carani; Giovanni Guaraldi
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

5.  Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy.

Authors:  Ana Rita Gomes; Pedro Souteiro; Carolina Germana Silva; Bernardo Sousa-Pinto; Francisco Almeida; António Sarmento; Davide Carvalho; Paula Freitas
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

6.  Testosterone Insufficiency in Human Immunodeficiency Virus-Infected Women: A Cross-Sectional Study.

Authors:  Ellen T M Laan; Jan M Prins; Rik H W van Lunsen; Pythia T Nieuwkerk; Marian A F Nievaard-Boon
Journal:  Sex Med       Date:  2018-12-03       Impact factor: 2.491

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.